Morepen Laboratories Share Price Target From 2025 to 2030
Morepen Laboratories Share Price Target From 2025 to 2030: Morepen Laboratories Ltd. is an Indian drug company engaged in the business of production and selling of active pharmaceutical ingredients (APIs), formulations, and diagnostic products. The company has pervasive reach in the health care sector through over-the-counter (OTC) offerings like best sellers Burnol, Lemolate, and Dr. Morepen.
Leadership Team
The company is directed by Managing Director and Chairman Sushil Suri, who has widened its market horizon and diversified its manufacturing capabilities for Morepen during his tenure with the firm.
Company Size & Market Position
- Market Capitalization: ₹2,711 Crores
- Number of Employees: Over 2,000
- Industry Position: Industry behemoth niche competition from players like Sun Pharma, Dr. Reddy’s, and Cipla.
- Competitive Advantage: Diversified R&D strength, broad product line, and improving penetration in the diagnostics business.
2. Financial Health: How Strong Is It?
Revenue & Profit Trends
There has been consistent revenue growth of Morepen Laboratories in the past five years fueled by its strong API business and expansion of diagnostic devices.
- Earnings Per Share (EPS): ₹2.30
- Return on Capital (ROC): 11.82%
- Book Value per Share: ₹20.27
- Debt to Equity Ratio: 0.03 (Low debt, financially strong)
The company’s financial health is sound with good cash flows financing its operations.
3. Stock Performance: How Does It Behave?
Important Stock Information
- Current Price: ₹49.89
- 52-Week High: ₹100.90
- 52-Week Low: ₹38.55
- P/E Ratio: 21.51 (Industry Average: 32.21)
- Market Cap: ₹2,710 Crores
Technical Performance
- RSI (14): 38.0 (Neutral)
- MACD (12, 26, 9): -4.5 (Bearish)
- ADX: 51.0 (Strong trend but volatile)
- ROC (21): -22.7 (Weak short-term momentum)
- ATR: 3.1 (Moderate volatility)
Its rising business segments are having favorable long-term prospects with short-term bearish nature.
4. Shareholding Pattern
- Retail Investors & Others: 60.48%
- Promoters: 35.65% (Remained constant last quarter)
- Foreign Institutional Investors (FIIs): 2.22% (From 2.08%)
- Domestic Institutions: 1.64%
The rise in FII holding reflects enhanced institutional investor sentiment.
5. Morepen Laboratories Share Price Target (2025-2030)
| YEAR | SHARE PRICE TARGET (₹) |
| 2025 | ₹120 |
| 2026 | ₹180 |
| 2027 | ₹240 |
| 2028 | ₹300 |
| 2029 | ₹360 |
| 2030 | ₹420 |
These are indications of Morepen Laboratories’ potential growth, better market penetration, and bullish institutions.
6. Growth Potential: What’s Next?
Drivers of Future Growth
- APIs Growth: Increased demand for APIs worldwide, especially in the U.S. and Europe.
- Diagnostic Segment Growth: Increased demand for home diagnostic kit and self-medication products.
- New Drug Approvals: Research and development of specialty drugs underway.
- Overseas Expansion: Geographical expansion overseas of Morepen’s exports, which could be a future revenue growth driver.
Risks to Consider
- Volatility in the Market: Short-term volatility of the stock in the market.
- Regulatory Challenges: Compliance with universal pharmaceutical regulations.
- Competition: Strong competition from incumbent players like Sun Pharma and Cipla.
7. FAQs For Morepen Laboratories Share Price
1. Is Morepen Laboratories a good long-term bet?
Yes, Morepen Laboratories has good fundamentals, healthier pipeline of products, and increased institutional demand and thus is a good long-term investment bet.
2. What will be Morepen Labs estimated share price by 2025?
2025 target price is approximately ₹120 on the growth trajectory of the company.
3. Why was Morepen Labs’ share price volatile recently?
The share price has been short-term volatile depending on sector movement, technicals, and sentiment. Its long-term perspective is bullish.
4. Does Morepen Labs give dividends?
Morepen Laboratories does not give dividends as it invests profit into business growth.
5. What would be the drivers that would drive the share price of Morepen Labs in the future?
The major drivers are growth in API business, growth in diagnostic devices, growth in exports, and new launches.
Morepen Laboratories can be a sound investment proposal for long-term investors. With its healthy balance sheets, steady rise in revenues, and expansion plan, the company can be a long-term winner. Investors must be careful towards market trends as well as regulatory shifts in the industry before investing.
